Mirati Therapeutics, Inc. (MRTX) Major Shareholder Venbio Select Advisor Llc Purchases 650,000 Shares
Mirati Therapeutics, Inc. (NASDAQ:MRTX) major shareholder Venbio Select Advisor Llc bought 650,000 shares of the business’s stock in a transaction on Thursday, November 16th. The shares were acquired at an average cost of $13.00 per share, with a total value of $8,450,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Mirati Therapeutics, Inc. (NASDAQ:MRTX) traded up $4.95 on Friday, reaching $19.00. The company had a trading volume of 3,032,900 shares, compared to its average volume of 551,700. Mirati Therapeutics, Inc. has a 1 year low of $2.70 and a 1 year high of $19.25.
Mirati Therapeutics (NASDAQ:MRTX) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.16. analysts anticipate that Mirati Therapeutics, Inc. will post -2.78 earnings per share for the current fiscal year.
Several research firms have issued reports on MRTX. HC Wainwright reissued a “buy” rating on shares of Mirati Therapeutics in a research note on Tuesday, November 7th. Zacks Investment Research raised Mirati Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 7th. ValuEngine raised Mirati Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. Jefferies Group LLC set a $5.00 price objective on Mirati Therapeutics and gave the company a “hold” rating in a research note on Friday, August 4th. Finally, Leerink Swann raised Mirati Therapeutics from a “mkt perform” rating to an “outperform” rating and set a $9.00 price objective for the company in a research note on Tuesday. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Mirati Therapeutics presently has a consensus rating of “Buy” and an average target price of $13.71.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Sabby Management LLC lifted its holdings in Mirati Therapeutics by 2.1% in the second quarter. Sabby Management LLC now owns 255,100 shares of the biotechnology company’s stock worth $921,000 after acquiring an additional 5,365 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Mirati Therapeutics by 22.9% in the first quarter. Bank of New York Mellon Corp now owns 63,004 shares of the biotechnology company’s stock worth $328,000 after purchasing an additional 11,753 shares during the last quarter. Susquehanna International Group LLP increased its position in shares of Mirati Therapeutics by 46.5% in the second quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock worth $184,000 after purchasing an additional 16,030 shares during the last quarter. KCG Holdings Inc. bought a new position in shares of Mirati Therapeutics in the first quarter worth approximately $106,000. Finally, Citadel Advisors LLC bought a new position in shares of Mirati Therapeutics in the third quarter worth approximately $268,000. 59.49% of the stock is owned by institutional investors.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.